Payment overview · 2025
General Payments
$278.30
15 reported records · 7 companies
Healthcare provider profile · identity verified
Yared A. Gebreyesus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STAFFORD, VA · NPI 1366432692
Verified facts
What the public records show
CMS Open Payments records show Yared A. Gebreyesus, M.D. received $278.30 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $116.98 | 42.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.76 | 21.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.79 | 11.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.19 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.68 | 5.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.90 | 5.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $12.00 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.30 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $91.82 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $91.82 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.76 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.76 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $12.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 281 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 96 |
| Metformin Hcl | Metformin Hcl | 234 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 68 |
| Losartan Potassium | Losartan Potassium | 197 | 69 |
| Gabapentin | Gabapentin | 167 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 35 |
| Lisinopril | Lisinopril | 140 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 36 |
| Furosemide | Furosemide | 103 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 34 |
| Trazodone Hcl | Trazodone Hcl | 97 | 31 |
| Alendronate Sodium | Alendronate Sodium | 96 | 32 |
| Ozempic | Semaglutide | 93 | 17 |
| Carvedilol | Carvedilol | 89 | 30 |
| Famotidine | Famotidine | 84 | 31 |
| Eliquis | Apixaban | 73 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 21 |
| Glipizide | Glipizide | 68 | 21 |
| Pregabalin | Pregabalin | 63 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 34 |
| Glipizide Er | Glipizide | 62 | 16 |
| Tramadol Hcl | Tramadol Hcl | 61 | 25 |
| Allopurinol | Allopurinol | 58 | 19 |
| Meloxicam | Meloxicam | 58 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Omeprazole | Omeprazole | 55 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 12 |
| Trulicity | Dulaglutide | 50 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 17 |
| Memantine Hcl | Memantine Hcl | 47 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 18 |
| Atenolol | Atenolol | 44 | 14 |
| Glimepiride | Glimepiride | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 19 |
| Metformin Hcl Er | Metformin Hcl | 39 | 15 |
| Montelukast Sodium | Montelukast Sodium | 39 | 15 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 17 |
| Jardiance | Empagliflozin | 30 | 12 |
| Prednisone | Prednisone | 30 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Valsartan | Valsartan | 29 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Finasteride | Finasteride | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.30 · 15 records | Amgen Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, EVENITY, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error